TITLE:
DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer

CONDITION:
Breast Cancer

INTERVENTION:
YMB 1002

SUMMARY:

      The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in
      patients with metastatic and/or recurrent breast cancer who may have received previous
      hormone treatment but have not had exposure to anthracycline treatment. Stratification
      allocation will be within the following subgroups:

        1. Prior cytotoxic treatment;

        2. Estrogen receptor status;

        3. ECOG performance status;

        4. Number of cycles of chemotherapy.
    

DETAILED DESCRIPTION:

      Endpoints of the trial are as follows:

      primary: overall survival; secondary: response rate, progression free survival, toxicity,
      neurocognitive function.
    

ELIGIBILITY:
Gender: Female
Age: 16 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Histological proof of breast cancer

          -  Documented evidence of metastatic and/or recurrent breast cancer

          -  Presence of at least one bi-dimensional or uni-dimensional lesion

          -  ECOG status 0, 1 or 2

          -  Quality of life
      
